PVLA
NASDAQ · Biotechnology
Palvella Therapeutics Inc
$126.84
-1.48 (-1.15%)
Open$127.55
Previous Close$128.32
Day High$130.79
Day Low$125.45
52W High$151.18
52W Low$20.20
Volume—
Avg Volume228.2K
Market Cap1.62B
P/E Ratio—
EPS$-3.70
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-58.4% upside
Current
$126.84
$126.84
Target
$52.81
$52.81
$42.56
$52.81 avg
$76.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 485.93M | 428.36M | 158.95M |
| Net Income | -97,434,771 | -77,301,916 | 26.26M |
| Profit Margin | -57.3% | -54.5% | 16.5% |
| EBITDA | -97,434,771 | -81,596,467 | 46.23M |
| Free Cash Flow | — | — | 10.92M |
| Rev Growth | +13.4% | +13.4% | +20.5% |
| Debt/Equity | 0.63 | 0.63 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |